HRX 2022: GPX Inc: Novel AI Algorithmic Blood Biomarker Monitoring

HRX 22 - GPX Inc. CEO Javier Echenique (GPX Inc., Boston, MA, US) joins us to discuss CardioID - a novel AI Algorithm-based "bloodless blood test" that uses NT-proBNP biomarkers in patient

Applied Sciences November-1 2020 - Browse Articles

先端AIのベンチャーが登場するSXSW2023のピッチファイナリスト

Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

Molecules, Free Full-Text

HRX 22

PDF) Association of Vegetable and Fruit Consumption with Urinary

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

Sean (Shunsuke) Matsuoka på LinkedIn: HRX 2022: GPX Inc: Novel AI

Digital Health